If you have been reading about WADA prohibited list and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-29. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Atul Malhotra is the Vice Chair of Medicine for Research and Research Chief of pulmonary, critical care, sleep medicine, and physiology at the University of California, San Diego's Medical School. In addition, he is the Peter C. Farrell Presidential Chair and tenured professor of medicine at the same university. He is the author of almost 600 original research publications and over 300 reviews and book chapters.
== Medicinal uses == It is used to heal cuts and stop minor external bleeding in Fiji but its medicinal properties are still yet to be fully discovered. It is also a very popular local antiseptic medicine in Mizoram State of India, it is known locally as Japan Hlo. Its use has also been reported in the state of Arunachal Pradesh; fresh leaves are pounded and then applied over lacerations to stop bleeding and subsequent healing. In Bangladesh used to treat gastric ulcer and as a local antiseptic. The antioxidant activity and anthelmintic (anti-parasitic) activity of Mikania micrantha leaves has been studied.
Defence Secretary Grant Shapps says six new warships will help fight the "conflicts of the future". 15 May – Rishi Sunak is challenged in PMQs over the early release of dangerous criminals. David Lammy and John Healey visit Ukraine and confirm Labour support. Sir Robert Buckland denies that he concealed lobbying efforts of Natalie Elphicke. Baroness Smith of Basildon says that hereditary peers will be phased out by any new Labour government. Former British Liberal Democrat MEP Graham Watson announces he will be a candidate in the 2024 European Parliament election in Italy. The UK government agrees to make death by dangerous cycling a criminal offence punishable by up to 14 years in prison after a campaign by Sir Iain Duncan Smith, who proposed the measures as an amendment to the Criminal Justice Bill, and after MPs vote in favour of the amendment. The Rwanda Asylum Plan is expanded to include all failed asylum seekers rather than the original plan of those arriving in the UK after 1 January 2022. 16 May – The UK government announces plans to allow the use of debit cards in pub slot machines, which it argues will allow pubs, casinos and gambling venues to compete in an increasingly cashless society. The Green Party of England and Wales says it will take action against candidates who make or support antisemitic remarks following complaints. The Independent Parliamentary Standards Authority finds that Paul Maynard, MP for Blackpool North and Cleveleys, broke expenses rules by using public resources to produce "overtly political" material for the Conservative Party.
Sources: en.wikipedia.org
Reviews have also found that populations that are believed to be especially high consumers of aspartame, such as children and diabetics, are below the ADI for safe consumption, even considering extreme worst-case scenario calculations of consumption. In a report released on 10 December 2013, the EFSA said that, after an extensive examination of evidence, it ruled out the "potential risk of aspartame causing damage to genes and inducing cancer" and deemed the amount found in diet sodas safe to consume.
On 31 October 1899, General Sir Redvers Henry Buller, a much-respected commander, arrived in South Africa with the Army Corps, made up of the 1st, 2nd and 3rd divisions. Buller originally intended an offensive straight up the railway leading from Cape Town through Bloemfontein to Pretoria. Finding on arrival that British troops were under siege, he split his army corps into detachments to relieve the besieged garrisons. One division, led by Lieutenant General Lord Methuen, was to follow the Western Railway to the north and relieve Kimberley and Mafeking. A smaller force of 3,000, led by Major General William Gatacre, was to push north towards the railway junction at Stormberg and secure the Cape Midlands District from Boer raids and rebellions by Boer inhabitants. Buller led the major part of the army corps to relieve Ladysmith to the east. The initial results of this offensive were mixed, with Methuen winning bloody skirmishes in the Battle of Belmont on 23 November, the Battle of Graspan on 25 November, and at a larger engagement, the Battle of Modder River, on 28 November resulting in British losses of 71 dead and over 400 wounded. British commanders had been trained on the lessons of the Crimean War and were adept at battalion and regimental set pieces, with columns manoeuvring in jungles, deserts and mountainous regions. What British generals failed to comprehend was the impact of destructive fire from trench positions and the mobility of cavalry raids.
Moreover, various protocols and methods of analyzing IDPs, such as studies based on quantitative analysis of GC content in genes and their respective chromosomal bands, have been used to understand functional IDP segments.
Sources: en.wikipedia.org
=== Genetics === A malignant peripheral nerve sheath tumor is rare, but is one of the most common non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) in the pediatric population. Neurofibromatosis type 1 (NF-1) is a risk factor for developing MPNSTs. NF-1 is a genetic disorder caused by a mutation on chromosome 17. The lifetime risk of patients with NF-1 developing MPNSTs has been estimated at 8–13%, with a yearly risk of developing MPNSTs of 0.16% compared to 0.001% in the general population.
=== Biological === This is the method by which dissolved and suspended organic chemical components are eliminated through biodegradation, in which an optimal amount of microorganism is given to re-enact the same natural self-purification process. Through two distinct biological process, such as biological oxidation and biosynthesis, microorganisms can degrade organic materials in wastewater. Microorganisms involved in wastewater treatment produce end products such as minerals, carbon dioxide, and ammonia during the biological oxidation process. The minerals (products) remained in the wastewater and were discharged with the effluent. Microorganisms use organic materials in wastewater to generate new microbial cells with dense biomass that is eliminated by sedimentation throughout the biosynthesis process.
Recombinant human parathyroid hormone is an artificially manufactured form of the parathyroid hormone used to help treat hypoparathyroidism (under-active parathyroid glands) and osteoporosis. Recombinant human parathyroid hormone (Preotact) received market authorization in the European Union in April 2006 to treat osteoporosis in postmenopausal women at high risk of fractures. Preotact marketing authorisation was later voluntarily withdrawn in 2014 by the holder NPS Pharma. FDA approval (as Preos) was not granted in the US for the same indication due to hypercalcemia and injection device issues. Recombinant human parathyroid hormone (Natpara) was approved for medical use in the United States in January 2015, and received (as Natpar) conditional market authorization in the European Union in February 2017 as orphan drug. On 2019 Natpara was recalled in the US due to rubber particle issues emerging from daily use of the cartridge. Takeda announced in 2022 its decision to stop manufacturing Natpara/Natpar globally at the end of 2024.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.